Long-Term Results of Calcium Hydroxylapatite for Vocal Fold Augmentation
Long-Term Results of Calcium Hydroxylapatite for Vocal Fold Augmentation
复制标题
DOI：
10.1002/lary.21258
复制
发表时间：
2011-02-01
期刊：
影响因子：
2.6
通讯作者：
Rosen, Clark A.
中科院分区：
文献类型：
--
作者：
Carroll, Thomas L.;Rosen, Clark A.
目的/假设：研究显示，羟基磷灰石钙（CaHA）注射后12个月的增强数据对于声门闭合不全具有极好的结果;然而，该材料超过一年的寿命尚不清楚。我们的目的是报告的长期有效性CaHA作为声带注射评估数据从一个队列的患者接受注射声门insufficient.Study Design：回顾性图表review.Methods：患者接受CaHA注射声门功能不全的任何病因被认为是纳入本研究。将注射前评分和最佳注射后评分之间以及注射前和最近VHI-10评分之间的声音障碍指数（VHI）-10评分的变化用作主要结局指标，以确定获益的持续性或至获益丧失的时间。并发症之间的队列identified.Results：90例患者进行了108声带注射与CaHA进行了评价纳入。20例患者接受了22次注射，符合入选标准。22例受试者中有14例（64%）显示CaHA材料获益丧失。领取补助金的平均时间为18.6个月，从8个月到36个月不等。三个并发症中确定的原始队列的108 injections.Conclusions：CaHA仍然是一个安全有效的长期声带注射的平均长度为18.6个月的好处。在108例CaHA注射中观察到3例并发症。CaHA是一种长期注射剂，具有良好的跟踪记录，似乎不需要担心永久性或晚期并发症。
Objectives/Hypothesis: Studies have shown excellent results for 12-month post-injection augmentation data for calcium hydroxylapatite (CaHA) for glottal incompetence; however, the longevity of the material past one year was unknown. Our objective was to report the long-term effectiveness of CaHA as a vocal fold injectable by assessing data from a cohort of patients who underwent injection for glottal insufficiency.Study Design: Retrospective chart review.Methods: Patients who underwent CaHA injection for glottal insufficiency of any etiology were considered for inclusion in the study. The change in Voice Handicap Index (VHI)-10 scores between preinjection scores and best postinjection scores as well as between the preinjection and the most recent VHI-10 scores were used as primary outcome measures to determine the persistence of benefit or the time to loss of benefit. Complications among the cohort were identified.Results: Ninety patients who underwent 108 vocal fold injections with CaHA were evaluated for inclusion. Twenty patients with 22 injections met the criteria for inclusion. Fourteen of 22 (64%) subjects showed loss of benefit of the CaHA material. The average length of benefit was 18.6 months, with a range of 8 to 36 months. Three complications were identified among the original cohort of 108 injections.Conclusions: CaHA remains a safe and effective long-term vocal fold injectable with an average length of benefit of 18.6 months. Three complications were seen among 108 CaHA injections. CaHA is a long-term injectable with an excellent track record that does not appear to warrant concern for permanent or late complications.